Free tool · No account
Clinical trials for multiple myeloma
Multiple myeloma has a deep bench of trials, including CAR-T and bispecific antibodies. Which trials fit usually depends on how many prior treatments there have been.
566 recruiting trials. Showing a sample.
- recruitingNCT07111884
GMMG Multiple Myeloma Registry
The goal of this observational study is to collect long-term clinical follow-up data on patients with multiple myeloma who participated in a therapy study of the German-Speaking Myeloma Multicenter Group (GMMG). Target variables of interest are: Overall survival, progression-...
Listed by the study for Multiple Myeloma. Record updated 2025-08-08.
Sponsored by Prof. Dr. Hartmut GoldschmidtFull details on ClinicalTrials.gov → - recruitingPhase 4NCT07907211
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy. The main questions it aims to answer are: Does rivaro...
Listed by the study for Multiple Myeloma. Record updated 2026-10-30.
Sponsored by Chen LijuanFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT06669247
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be ...
Listed by the study for Relapsed/Refractory Multiple Myeloma. Record updated 2026-08-05.
Sponsored by Regeneron PharmaceuticalsFull details on ClinicalTrials.gov → - recruitingNCT06760052
Longitudinal Data Registry of Plasma Cell Dyscrasia
The goal of this multicenter observational study is to better understand the clinical and molecular characteristics, disease progression, treatment response, and clinical outcomes of patients with plasma cell dyscrasias, including monoclonal gammopathy of undetermined signific...
Listed by the study for Multiple Myeloma and Other Plasma Cell Neoplasms. Record updated 2026-08-03.
Sponsored by Shanghai Zhongshan HospitalFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT06785415
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immuno...
Listed by the study for Recurrent Multiple Myeloma. Record updated 2026-06-25.
Sponsored by Mayo ClinicFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04025450
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.
Listed by the study for Multiple Myeloma. Record updated 2019-07-19.
Sponsored by The First Affiliated Hospital of Soochow UniversityFull details on ClinicalTrials.gov → - recruitingNCT07763054
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
This is a single-center, single-arm, observational clinical study evaluating the efficacy and safety of low-dose liposomal amphotericin B (50 mg/day, intravenous, once daily) for the prevention of invasive fungal infections in adult patients (aged 18-75 years) with hematologic...
Listed by the study for Multiple Myeloma. Record updated 2026-08-13.
Sponsored by Haikou Affiliated Hospital of Central South University Xiangya School of MedicineFull details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT07085559
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
Listed by the study for Multiple Myeloma (MM). Record updated 2025-07-25.
Sponsored by Anhui Provincial HospitalFull details on ClinicalTrials.gov → - recruitingPhase 2NCT05695508
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetam...
Listed by the study for Multiple Myeloma. Record updated 2025-12-24.
Sponsored by University of Heidelberg Medical CenterFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06799026
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM). The names of the study drugs and vaccine involved in t...
Listed by the study for Multiple Myeloma. Record updated 2026-05-07.
Sponsored by David AviganFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this multiple myeloma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.